Parkinson's research which will focus on the role of antioxidant Coenzyme Q10 in the condition, has been announced.
Coenzyme Q10 is a natural antioxidant that helps cells to create energy and defend against toxic chemicals such as those with Parkinson's battle against.
The study, to be funded by the Michael J Fox Foundation, intends to focus on a new formulation of Coenzyme Q10 and Vitamin E.
Dr Kieran Breen, director of research and development at Parkinson's UK, said that the treatment could "pave the way" for treatments that could slow down the development of the condition.
"Coenzyme Q10 has shown potential in human trials, but problems with finding and delivering the right dose have slowed our progress," he explained.
This comes after researchers from Kaiser Permanente Northern California found that patients who have used amphetamines such as Benzedrine and Dexedrine could have a higher risk of developing Parkinson's disease.